Atop the list of concerns among political onlookers in what is shaping up to be a fierce attempt by Pfizer to acquire AstraZeneca: Jobs -- where will they be slashed and how many will lose out?
WuXi PharmaTech has announced its manufacturing business, Syn-The-All (STA) Pharmaceuticals Co., Ltd., has broken ground on an R&D and manufacturing site in China.
CRO Quintiles on Monday announced that it has signed an agreement to acquire Encore Health Resources, which offers health-information analytics and electronic health record (EHR) services.
A Brazilian Court in Sao Paulo has ordered Eli Lilly pay about $450m for exposing former employees of its subsidiary to hazardous substances in a manufacturing facility operated between 1977 and 2003.
Chinese CRO Tigermed has entered a definitive agreement to acquire a majority stake in the ownership of CRO Frontage Laboratories for $50.25m in cash, some of which the company will use to expand clinical capacity in New Jersey.
Onyx Scientific, a UK contract development and manufacturing organisation (CDMO) has completed an API (active pharmaceutical ingredient) production deal for Neuronascent, a US company developing neurological therapies.
The counterfeiting of over-the-counter drugs is a growing problem according to an ex-criminal prosecutor, but the nature of such medicines means the problem often goes unreported.
As part of an effort to provide more certainty, India’s CDSCO (Central Drugs Standards Control Organization) has offered up a new compensation formula for trial participants who are killed or injured during a trial.
CROs (contract research organizations) are more likely than sponsors to report frequent application of QbD (quality by design) principles for clinical research, though neither group seems particularly comfortable with QbD yet, according to preliminary...
As the Pfizer-AstraZeneca mega-merger seems to be pushing towards a deal, early phase CROs may be the first to suffer for a short period of time directly after the merger is complete, some say, while others don't seem to think there will be much...
AMRI has upped its guidance following a quarter that saw unprecedented demand from its once-troubled Burlington plant and the integration of recent acquisition Cedarburg commence.
Scientists are scouring the seas for novel bioactive compounds as part of PharmaSea, a four-year project which has already turned up interesting compounds from samples of mud, sediment and sea life.
Huntingdon Life Sciences has acquired contract research and animal models firm Harlan Laboratories, making it the third largest preclinical research organisation, according to the company.
Teva will close eleven of its manufacturing plants and is considering shutting another 16 as part of a campaign to cut annual spending by $2bn (€1.4bn).
As the European Medicines Agency (EMA) has implemented the majority of elements of the new pharmacovigilance legislation, the agency is now reporting that the main objectives of the legislation are largely being achieved.
Medpace Laboratories, Singapore will serve and support new and existing Medpace pharmaceutical clients conducting clinical research in the rapidly expanding Asia Pacific region.
Vince & Associates, a contract research organisation (CRO) conducting early stage and complex clinical trials, is building a $5m expansion designed to recruit and retain volunteers.
Quintiles and Covance have re-iterated previous CROs’ upbeat stances on the prospect for further pharma M&A as they both reported revenue growth for the quarter.
DrugDev, a network of active clinical trial doctors, has acquired TrialNetworks, a cloud-based suite of collaborative trial management apps and site-facing tools designed to improve processes, ensure transparency and streamline timelines for clinical...
Boehringer Ingelheim says the Saudi Arabian market is a huge drive for big pharma as it teams with local firms to manufacture secondary packaging for 26 products.
Bayer says it will become the OTC leader in North America having acquired Merck & Co.’s consumer health business for $14.2bn (€10.2bn), in the latest shift in Big Pharma assets.
Bayer has inked a deal with preclinical CRO Cenix BioScience to use its genome-scale RNA interference (RNAi) platform to target an undisclosed disease.
Pfizer will keep a “substantial” level of manufacturing in the UK if it takes over AstraZeneca, said the CEO in a letter to the country’s Prime Minister.
Hospira says approval for its new manufacturing facility in India is still on track despite receiving a Form 483 form the US FDA with ten observations.
Sun Pharma says the closure of a Michigan plant employing 179 staff is necessary in order to consolidate its US manufacturing network, and not related to its Ranbaxy acquisition.
AstraZeneca has chosen big data and analytics services provider Sinequa, to index millions of R&D documents for use in a search platform providing “sub-second” answers to research questions.
Aesica has secured a Technology Strategy Board grant to fund a high-value chemical manufacturing process with the winning process set to improve the sustainability of an active pharmaceutical Ingredient (API).
The European Medicines Agency (EMA) has published guidance for departing employees intended to ensure there is no conflict of interest in their new roles.
Colorcon today opened an expanded facility in Goa, India to scale up production of tablet coatings and excipients for pharmaceutical manufacturers in South Asia.
Experts have predicted emerging Indian and Chinese markets will outpace Western markets as the $2.3bn oral solid dosage form (OSDF) excipients global market grows at a sustainable rate.
Biopharma is ramping up the outsourcing of some of the easier tests while tasks such as downstream process development and QbD services are being outsourced less, according to a new survey.
Capsugel is no longer a simple capsule provider but a differentiated player in the CDMO industry, the firm says as it wins a scale-up manufacturing contract for Chiasma and Roche’s oral octreotide candidate.
The recent rumours of mega-mergers are behind a sudden drop in the share value of contract research organisations (CROs) but should bring long-term benefits, says an analyst.
Researchers in Switzerland have devised a form of gold nanoparticle that shows promise as a weapon against tumours and as a delivery vehicle for drugs.
As regulators incentivise the development of orphan medicines and high price tags for the drugs continue to rise, logistics specialists are offering new ways to get the drugs to the increasingly small patient populations.
Toxicology services provider Harlan Laboratories has selected Invenium Pharmacology as its exclusive agent for Harlan’s Contract Research Services (CRS) in Australia, Southeast Asia and New Zealand.
A stake in Brazil-based wholesaler Profarma will increase AmerisourceBergen’ global presence already strengthened by the World Courier acquisition, the firm says as it reports a robust Q2.
As pharma manufacturers look to cut costs and increase quality, over 70% of industry executives interviewed for a recent CPhI report say they are actively investing in manufacturing techniques and technologies to achieve these goals.
The relationship between private equity (PE) management and that of its CRO is “pivotal,” according to the Chairman of one pharma group, as PE’s undefined objectives and exit strategies are leaving sponsors uncomfortable.
Endo Pharmaceuticals, which previously lost a bid to acquire a migraine treatment, has now acquired worldwide rights to Sumavel DosePro (sumatriptan injection) for subcutaneous use, which is a needle-free delivery system for Zogenix’s migraine treatment...
